公开(公告)号：US20250076299A1

公开(公告)日：2025-03-06

申请号：US18520251

申请日：2022-03-31

Applicant: MICAN Technologies Inc. ,  Japan as Represented by the Director-General of National Institute Institute of Infectious ,  Osaka University

Inventor： Ryosuke Suzuki ,  Maml Matsuda ,  Masamichi Muramatsu ,  Kyoko Saito ,  Masayoshi Fukasawa ,  Kentaro Hanada ,  Atsushi Yamanaka ,  Kazuo Miyazaki ,  Misuzu Yamada ,  Jun Shimizu

IPC: G01N33/569 ,  C12N7/00

Abstract: The present invention aims to provide a method for testing the function of antibodies that uses safe antigens and gives results more quickly. The present invention relates to a method for determining antibody-dependent enhancement ability of antibodies, including contacting, in the presence of a test antibody, Fcγ receptor-expressing cell with single round infectious virus particles containing a gene with a region encoding a labeled protein and a region encoding non-structural (NS) proteins 1 to 5 of the yellow fever virus genome, a capsid protein of a virus, and an outer shell protein (Envelope) of a virus, wherein when the measured label is greater than that of a negative control cell, the test antibody is determined to have an antibody-dependent enhancement ability, and the like.

公开(公告)号：US20220412958A1

公开(公告)日：2022-12-29

申请号：US17777988

申请日：2020-11-19

Applicant: MiCAN Technologies Inc. ,  Nissui Pharmaceutical Co., Ltd.

Inventor： Kazuo Miyazaki ,  Jun Shimizu ,  Yoshitaka Tanaka

IPC: G01N33/50 ,  G01N33/543 ,  G01N33/68

Abstract: [Problem]
To find a method having higher stability, reproducibility, economic efficiency, and operation easiness in an evaluation method of safety of a substance in vitro, by using human immortalized myeloid cells.
[Solving Means]
A method for evaluating the skin sensitizing property and/or the pyrogenic property of a test substance, a method for detecting a skin sensitizer and/or a pyrogen in a sample, and a method for evaluating the action of a sample on a function of immune cells, each using human immortalized myeloid cells and including measuring the production amount of IL-6 and/or IL-8 in a culture medium of human immortalized myeloid cells.

公开(公告)号：US20230374452A1

公开(公告)日：2023-11-23

申请号：US18030965

申请日：2021-10-06

Applicant: MiCAN Technologies Inc. ,  OSAKA UNIVERSITY

Inventor： Jun Shimizu ,  Naomi Tanga ,  Misuzu Yamada ,  Kazuo Miyazaki ,  Tatsuo Shioda ,  Emi Nakayama ,  Tadahiro Sasaki ,  Ritsuko Koketsu

IPC: C12N5/078 ,  C07K14/53 ,  C12N9/48 ,  C12Q1/70 ,  C12N5/10 ,  C12N7/02

CPC classification number: C12N5/0634 ,  C07K14/53 ,  C12N9/485 ,  C12Q1/70 ,  C12N5/10 ,  C12N7/02 ,  C12Y304/17023

Abstract: The present invention provides human cells that can be stably infected with coronavirus, as human cells for research on infection with coronavirus such as SARS-CoV-2, as well as, by utilizing the cells, a method for confirming the presence of a coronavirus in a sample, a method for producing a coronavirus, and a method for evaluating the presence or absence of anti-coronavirus activity of a test sample or a substance having an anti-coronavirus neutralizing action in a test sample. Specifically, the present invention relates to a method for preparing a coronavirus-infectious immortalized human myeloid cell, including introducing ACE2 and TMPRSS2 into an immortalized human myeloid cell, and the like.

公开(公告)号：US20210277361A1

公开(公告)日：2021-09-09

申请号：US17271902

申请日：2019-08-26

Applicant: MICAN TECHNOLOGIES INC. ,  KUMAMOTO UNIVERSITY ,  OSAKA UNIVERSITY

Inventor： Kazuo MIYAZAKI ,  Atsushi YAMANAKA ,  Minoru OKADA ,  Satoru SENJYU

IPC: C12N5/10 ,  G01N33/50 ,  A61K39/12

Abstract: The present invention has been made in view of a problem regarding stability, reproducibility, economy, and easiness of operation in studies for a monocyte- or dendritic cell-mediated infectious microorganism, and is directed to provide a method for maintenance culturing a monocyte- or dendritic cell-mediated infectious microorganism utilizing a monocyte having a proliferative capacity. The present invention is based on the finding that a dengue virus efficiently infects a proliferable human monocytic cell obtained by introducing a gene into a CD14-positive cell and a cell having a phagocytic capacity obtained by inducing the monocytic cell to differentiate (e.g., dendritic cell) and proliferates therein. Thus, provided is a novel method for evaluating a pharmaceutical such as a compound or a vaccine for treating an infection with a monocyte- or dendritic cell-mediated infectious microorganism.